technetium-tc-99m-exametazime and Carcinoma--Bronchogenic

technetium-tc-99m-exametazime has been researched along with Carcinoma--Bronchogenic* in 2 studies

Other Studies

2 other study(ies) available for technetium-tc-99m-exametazime and Carcinoma--Bronchogenic

ArticleYear
Quantitative single-photon emission tomography for tumour blood flow measurement in bronchial carcinoma.
    European journal of nuclear medicine, 1993, Volume: 20, Issue:7

    A single-photon emission tomography (SPET) technique for the absolute measurement of tumour perfusion is described. Phantom studies have shown that source-background ratios are dependent upon source size and radial position within the phantom. A means of correcting source-background count ratios for these variables has been developed and used to correct tumour-lung ratios obtained in 28 patients with bronchial carcinomas who underwent technetium-99m hexamethylpropyleneamine oxime (99mTc-HMPAO) SPET. On SPET images, the normal lung appears as a relatively homogeneous background. The relationship between 99mTc background concentration (kBq/ml) and counts/pixel was determined from phantom studies and the tumour 99mTc concentration from the background 99mTc concentration and corrected tumour-lung ratio. The total activity of the lipophilic 99mTc-HMPAO species injected was measured. The activity reaching the systemic circulation (Asys) was obtained by subtracting the activity trapped in the pulmonary circulation (obtained from background 99mTc concentration and lung volume). Tumour blood flow may then be calculated from fraction of Asys contained in the tumour provided cardiac output and extraction fraction are known. Blood flow through the central region of tumours ranged from zero to 59.0 (mean 14.1) ml min-1 100 g-1 and through the whole tumour from 0.6 to 68.0 (mean 20.6) ml min-1 100 g-1.

    Topics: Blood Flow Velocity; Carcinoma, Bronchogenic; Humans; Lung Neoplasms; Models, Structural; Organotechnetium Compounds; Oximes; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon

1993
Initial experience with Tc-99m-HM-PAO in the study of brain tumors.
    European journal of nuclear medicine, 1988, Volume: 14, Issue:1

    A preliminary study of the distribution of the 99mTc complex of hexamethylpropylene amine oxime (HM-PAO) in 12 patients with brain neoplasms before, during, and after radiotherapy has been performed. Untreated brain tumors were found to exhibit a range of 99mTc-HM-PAO uptake, varying from areas of markedly increased isotope activity to photopenic areas, when compared to normal brain tissue. A ratio of 99mTc-HM-PAO tumor uptake to contralateral normal tissue uptake was calculated prior to and during radiotherapy. This ratio tended to return towards unity in lesions responding to therapy. A predictable alteration in whole brain 99mTc-HM-PAO uptake during radiotherapy was not demonstrated. Unlike the radiolabeled amines, 99mTc-HM-PAO localizes in primary tumors, probably indicating that its uptake mechanism is independent of non specific amine receptors. 99mTc-HM-PAO may be useful in the study of brain tumor physiology and response to therapy.

    Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Female; Glioma; Humans; Lung Neoplasms; Male; Middle Aged; Organometallic Compounds; Oximes; Technetium Tc 99m Exametazime; Tomography, Emission-Computed

1988